申请人:SCHERING CORPORATION
公开号:EP0226312A2
公开(公告)日:1987-06-24
The rise in intraocular pressure associated with the use of steroidal anti-inflammatory drugs is controlled by use of angiotensin converting enzyme inhibitors.
For the purposes of the invention, the preferred ACE inhibitor is 7-[N-(1(S)-carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid.
使用类固醇消炎药会导致眼压升高,使用血管紧张素转换酶抑制剂可控制眼压升高。 就本发明而言,首选的血管紧张素转换酶抑制剂是 7-[N-(1(S)-羧基-3-苯基丙基)-(S)-丙氨酰]-1,4-二硫杂-7-氮杂螺[4.4]壬烷-8(S)-羧酸。